An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma Initially Treated with an Injection of Proteasome Inhibitor-Based Therapy
Phase of Trial: Phase IV
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary) ; Bortezomib; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda
- 20 Jul 2018 Planned primary completion date changed from 31 Jan 2020 to 28 Feb 2020.
- 09 Jul 2018 Planned End Date changed from 30 Apr 2021 to 31 May 2021.
- 02 Feb 2018 Status changed from not yet recruiting to recruiting.